Skip to main content

PreGene Closes $21 Million Financing for Fusion/Nano-Antibody Drugs

PreGene, a Shenzhen biotech, closed a $21 million B financing as it looks forward to an IPO on the Hong Kong exchange. The funding was led by Haier Biomedical . PreGene  claims to have the world's only fusion drug and nano-antibody drug biotechnology R&D platform. Founded in 2012, PreGene is also developing TCR-T, CAR-T and stem cell candidates. Its BCMA CAR-T candidate is approved to start clinical trials in China . More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.